Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2019

25.10.2018 | Review

Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis

verfasst von: Michael M. Jonczyk, Jolie Jean, Roger Graham, Abhishek Chatterjee

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer surgical techniques are evolving. Few studies have analyzed national trends for the multitude of surgical options that include partial mastectomy (PM), mastectomy without reconstruction (M), mastectomy with reconstruction (M+R), and PM with oncoplastic reconstruction (OS). We hypothesize that the use of M is declining and likely correlates with the rise of surgery with reconstructive options (M+R, OS).

Methods

A retrospective cohort analysis was conducted using the ACS-NSQIP database from 2005 to 2016 and ICD codes for IBC and DCIS. Patients were then grouped together based on current procedural terminology (CPT) codes for PM, M, M+R, and OS. In each group, categories were sorted again based on additional reconstructive procedures. Data analysis was conducted via Pearson’s chi-squared test for demographics, linear regression, and a non-parametric Mann- Kendall test to assess a temporal trend.

Results

The patient cohort consisted of 256,398 patients from the NSQIP data base; 197,387 meet inclusion criteria diagnosed with IBC or DCIS. Annual breast surgery trends changed as follows: PM 46.3–46.1% (p = 0.21), M 35.8–26.4% (p = 0.001), M+R 15.9–23.0% (p = 0.03), and OS 1.8–4.42% (p = 0.001). Analyzing the patient cohort who underwent breast conservation, categorical analysis showed a decreased use of PM alone (96–91%) with an increased use of OS (4–9%). For the patient cohort undergoing mastectomy, M alone decreased (69–53%); M+R with muscular flap decreased (9–2%); and M+R with implant placement increased (20–40%)—all three trends p < 0.0001.

Conclusion

The modern era of breast surgery is identified by the increasing use of reconstruction for patients undergoing breast conservation (in the form of OS) and mastectomy (in the form of M+R). Our study provides data showing significant trends that will impact the future of both breast cancer surgery and breast training programs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat De Lorenzi F, Loschi P, Bagnardi V, Rotmensz N, Hubner G, Mazzarol G, Orecchia R, Galimberti V, Veronesi P, Colleoni MA, Toesca A, Peradze N, Mario R Oncoplastic breast-conserving surgery for tumors larger than 2 centimeters: Is it oncologically safe? A matched-cohort analysis. Ann Surg Oncol 23 (6):1852–1859. https://doi.org/10.1245/s10434-016-5124-4 De Lorenzi F, Loschi P, Bagnardi V, Rotmensz N, Hubner G, Mazzarol G, Orecchia R, Galimberti V, Veronesi P, Colleoni MA, Toesca A, Peradze N, Mario R Oncoplastic breast-conserving surgery for tumors larger than 2 centimeters: Is it oncologically safe? A matched-cohort analysis. Ann Surg Oncol 23 (6):1852–1859. https://​doi.​org/​10.​1245/​s10434-016-5124-4
12.
Zurück zum Zitat Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF (2016) Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. Ann Surg Oncol 23(10):3190–3198. https://doi.org/10.1245/s10434-016-5407-9 CrossRefPubMed Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF (2016) Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. Ann Surg Oncol 23(10):3190–3198. https://​doi.​org/​10.​1245/​s10434-016-5407-9 CrossRefPubMed
15.
Zurück zum Zitat Surgeons, ACo (2018) ACS national surgical quality improvement program. ACS. Accessed 8/1/2018 Surgeons, ACo (2018) ACS national surgical quality improvement program. ACS. Accessed 8/1/2018
17.
Zurück zum Zitat Liang Y, Naber SP, Chatterjee A (2018) Anatomic and terminological description and processing of breast pathologic specimens from oncoplastic large volume displacement surgeries. Mod Pathol 31:1004–1011CrossRefPubMed Liang Y, Naber SP, Chatterjee A (2018) Anatomic and terminological description and processing of breast pathologic specimens from oncoplastic large volume displacement surgeries. Mod Pathol 31:1004–1011CrossRefPubMed
19.
Zurück zum Zitat Bazzarelli A, Zhang J, Arnaout A (2016) Patient-reported satisfaction following oncoplastic breast-conserving therapy. In: The American Society of Breast Surgeons Annual Meeting, Dallas, Texas, 4/13/2016 Bazzarelli A, Zhang J, Arnaout A (2016) Patient-reported satisfaction following oncoplastic breast-conserving therapy. In: The American Society of Breast Surgeons Annual Meeting, Dallas, Texas, 4/13/2016
26.
Zurück zum Zitat De Lorenzi F, Hubner G, Rotmensz N, Bagnardi V, Loschi P, Maisonneuve P, Venturino M, Orecchia R, Galimberti V, Veronesi P, Rietjens M (2015) Oncological results of oncoplastic breast-conserving surgery: Long term follow-up of a large series at a single institution: a matched-cohort analysis. Eur J Surg Oncol 42(1):71–77. https://doi.org/10.1016/j.ejso.2015.08.160 CrossRefPubMed De Lorenzi F, Hubner G, Rotmensz N, Bagnardi V, Loschi P, Maisonneuve P, Venturino M, Orecchia R, Galimberti V, Veronesi P, Rietjens M (2015) Oncological results of oncoplastic breast-conserving surgery: Long term follow-up of a large series at a single institution: a matched-cohort analysis. Eur J Surg Oncol 42(1):71–77. https://​doi.​org/​10.​1016/​j.​ejso.​2015.​08.​160 CrossRefPubMed
Metadaten
Titel
Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis
verfasst von
Michael M. Jonczyk
Jolie Jean
Roger Graham
Abhishek Chatterjee
Publikationsdatum
25.10.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5018-1

Weitere Artikel der Ausgabe 2/2019

Breast Cancer Research and Treatment 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.